Cargando…

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis

BACKGROUND & AIMS: Remodelling of extracellular matrix is crucial in progressive liver fibrosis. Collagen type III desposition has been shown in acute decompensation. Extratracellular matrix is compiled of deposition of various components. The role of basement membrane collagen type IV in advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehmann, Jennifer, Praktiknjo, Michael, Nielsen, Mette Juul, Schierwagen, Robert, Meyer, Carsten, Thomas, Daniel, Violi, Francesco, Strassburg, Christian P., Bendtsen, Flemming, Møller, Søren, Krag, Aleksander, Karsdal, Morten Asser, Leeming, Diana Julie, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cirrhosis and Liver Failure
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594031/ https://www.ncbi.nlm.nih.gov/pubmed/30739387 http://dx.doi.org/10.1111/liv.14070

Ejemplares similares

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
por: Madsen, Bjørn S., et al.
Publicado: (2020)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis
por: Burza, Maria Antonella, et al.
Publicado: (2014)

An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution
por: Pehrsson, Martin, et al.
Publicado: (2022)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients
por: Ohfuji, Satoko, et al.
Publicado: (2014)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

Bacterascites: A study of clinical features, microbiological findings, and clinical significance
por: Oey, Rosalie C., et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
por: Slack, A J, et al.
Publicado: (2013)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates
por: Blasi, Annabel, et al.
Publicado: (2021)

High plasma levels of betaine, a trimethylamine N‐Oxide‐related metabolite, are associated with the severity of cirrhosis
por: van den Berg, Eline H., et al.
Publicado: (2022)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation
por: Thiele, Maja, et al.
Publicado: (2021)

Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis
por: Arabi, Yaseen M, et al.
Publicado: (2012)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience
por: Verma, Anita, et al.
Publicado: (2020)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study
por: Yin, Dalong, et al.
Publicado: (2020)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study
por: Gitto, Stefano, et al.
Publicado: (2022)

Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease
por: Siddiqui, Mohammad S., et al.
Publicado: (2022)

Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump
por: Stirnimann, Guido, et al.
Publicado: (2022)

A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS ‐ Modified TIPS Score
por: Fürschuß, Luisa, et al.
Publicado: (2022)

An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection
por: Ruan, Dongsheng, et al.
Publicado: (2021)

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
por: Jiménez, César, et al.
Publicado: (2022)

The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis
por: Perramón, Meritxell, et al.
Publicado: (2022)

The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
por: Gioia, Stefania, et al.
Publicado: (2021)

Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
por: Saliba, Faouzi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_js27mgs63kl3ok2c927gh1vj0c